tbuckley/cabot-search huggingface dataset:
AB1128 Epidemiological Comparative Analysis in a Large Cohort of Rheumatoid Arthritis Patients: Results of the Spanish IMID Consortium
Authors: J. Tornero, A. Fernández-Nebro, F. Blanco, I. Gonzalez-Alvaro, R. Sanmarti, J. Maymo, J. Ballina, B. Fernández-Gutierrez, A. Olive, H. Corominas, A. Erra, A. Pluma, A. Alonso, R. Tortosa, M. Lόpez Lasanta, S. Marsal
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatoid arthritis (RA) is a complex disease of unknown etiology, involving both genetic and environmental factors. <h3>Objectives</h3> The aim of this study was to analyze the more relevant epidemiological characteristics in a large cohort of patients with RA and controls in the Spanish population. <h3>Methods</h3> A cross-sectional,comparative,multicenter study of patients with RA and hypernormal healthy subjects for IMID diseases was performed.All patients were recruited through the <i>Immune-Mediated Inflammatory Diseases</i> Consortium (IMIDC).The IMIDC is a network of Spanish biomedical researchers focused in the study of the molecular basis of IMID diseases.All patients included in the present study were selected from the outpatient clinics of 12 Rheumatology Departments at different Spanish university hospitals.An epidemiological questionnaire developed by experts at DNA National Bank was applied to obtain all data. <h3>Results</h3> 2,366 RA patients and 1,558 healthy subjects were included.77% of RA patients and 40% of controls were female.The mean age of patients with RA was 60±13 years and controls 49±7 years.The height and weight of controls was significantly higher than in patients with RA.The level of statistical significance was decreased by introducing gender and age as covariates.In our cohort,65% of patients with RA had no education or only primary education.Control subjects mostly had secondary or higher education.The physical exercise was significantly more frequent in controls.The gender and age affect the assessment of physical activity performed by both groups of patients.Regarding employment status,most patients with RA were housewives (43%) whereas in controls were external employers (44%).RA patients most frequently used public transportation (39%) while controls use their cars (52%).The mean consumption of tobacco, alcohol and coffee was higher in controls but the significance level decreased in multivariate analysis,confirming the influence of gender and age on these variables.The average number of children in RA patients was higher than controls,a difference that was not confirmed by including confounding factors. <h3>Conclusions</h3> In this large comparative study we describe for the first time the general epidemiological characteristics in patients with RA and healthy subjects representative of the Spanish population.RA patients are older as compared with controls and most of them are housewives with no education or primary education.The influence of gender confirms the significance level of physical activity,alcohol consumption, smoking, coffee intake, weight, height and average number of children. <h3>Disclosure of Interest</h3> None declared
Alveolar echinococcosis
Authors: Solange Bresson-Hadni, Isabelle Beurton, Brigitte Bartholomot, Dominique-Angèle Vuitton, Peter Kern, Georges Mantion, Jean-Philippe Miguet
Journal: Hepatology (1998)

In contrast, none of the healthy controls had antibodies to p105, only 23% had a single band to p60, and 3% had a positive response to the p86 peptide.Significant antibodies were noted among the other specified peptides in both HCV and HBV but not in the controls.We confirmed that chronic HCV and HBV patients demonstrate the presence of autoantibodies to peptides which are not usually found in the healthy individual.Although HCV is an RNA virus in the flavivirus family and HBV is a DNA virus in the Hepadnaviridae family, both chronic infectious states appear to induce an autoimmune component.Neither the viral induction of autoimmune responses 4 nor the clinical evidence of autoimmunity in these infections is new. 5Abuaf et al. 6 reported that 18% of chronic HCV patients had positive anti-nuclear antibodies compared with 3% among a normal blood donor population.However, the presence of significant autoantibodies may be misleading in diagnosis as many of these antibodies are thought to be found only in specific rheumatic or autoimmune diseases.The irregular patterns and the inconsistent findings among the patients suggest that the development of these autoantibodies are probably an epiphenomenon which is caused by tissue destruction and by the availability of protected proteins that are not normally seen by the individual' s immune system.However, in recent studies in which microbial infections triggered autoimmunity, the theory of molecular mimicry is suggested where some molecules of the microorganisms resemble those of the host. 7 As the host mounts a defense against the infectious agent, it inadvertently activates immune responses against the host' s own molecules.Segal et al. 7 further suggest that the production of interleukin (IL)-12 arouses the self-reactive immune cells.As Cassani et al. 1 stated, further studies are needed to assess the relevance of autoimmune response development and symptoms and as well as infectious disease progression.
Diabetes mellitus. A disease that is coming into focus
Authors: L. B. Salans
Journal: JAMA (1982)

<h3>Advances in Diabetes Research</h3> In recent years, there has been an enormous amount of progress in understanding and treating diabetes. Just a few years ago everyone thought of diabetes as a single disease. It is clear now that diabetes is a heterogeneous group of disorders, almost all of which have a genetic basis, but in which the genetic types vary. Not only does the insulin-dependent (juvenile onset) form of diabetes differ from non-insulin-dependent (maturity onset) diabetes, but even within each of these two types there appears to be heterogeneity. <h3>Genetics and Environment</h3> We know that insulin-dependent diabetes, for example, is associated with certain genetically determined histocompatibility antigens. The environment appears to determine whether this form of diabetes will be expressed clinically in the genetically susceptible individual. Non-insulin-dependent diabetes so far has not been associated with particular HLA antigens. Nevertheless, genetic factors clearly cause or contribute to this form of diabetes.
Transfusion Complications
Authors: Mark Falcon Lesses
Journal: JAMA (1965)

<h3>To the Editor:—</h3> InThe Journalof Nov 23, 1964 (<b>190</b>:773), appears an excellent editorial on the prevention of transfusion complications. There is, however, one suggestion to which exception can be taken, namely, that a major crossmatch in an antiglobulin system should be determined only in patients who have been pregnant or who have received previous transfusions. This is certainly less than an acceptable standard in today's blood-bank methodology. As a minimum standard, a major crossmatch in an antiglobulin system or its equivalent should be part of every compatibility test. I doubt that there are many transfusionists who would be willing to omit the indirect antiglobulin (Coombs') test as part of the routine examination of recipient's serum in every crossmatch. One other point should be stressed and that is the saving of a small sample of the patient's blood for at least<i>seven</i>days after each transfusion, as there
Echinacea for the Common Cold
Authors: Wendy L. Applequist
Journal: Annals of Internal Medicine (2003)

Letters7 October 2003Echinacea for the Common ColdWendy L. Applequist, PhDWendy L. Applequist, PhDFrom Missouri Botanical Garden; St. Louis, MO 63166-0299.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-7-200310070-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Barrett and colleagues' study (1) of an unrefined echinacea product, while elegant, was limited by poorly chosen and inadequately characterized source material. Clinical trials should begin with botanically identified raw material, with sources and processing described and representative voucher specimens of the whole plant or samples of the raw material preserved in a publicly accessible herbarium, unless a defined commercial product is to be studied. Shaklee Technica (Pleasanton, California) distributes an echinacea-containing product through multilevel marketing, but it is not the formulation provided to Barrett and colleagues.The product used by Barrett and colleagues was chemically analyzed ...References1. Barrett BP, Brown RL, Locken K, Maberry R, Bobula JA, D'Alessio D. Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:939-46. [PMID: 12484708] LinkGoogle Scholar2. Turner RB. Echinacea for the common cold: can alternative medicine be evidence-based medicine? [Editorial]. Ann Intern Med. 2002;137:1001-2. [PMID: 12484717] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Missouri Botanical Garden; St. Louis, MO 63166-0299. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment of the Common Cold with Unrefined Echinacea Bruce P. Barrett , Roger L. Brown , Kristin Locken , Rob Maberry , James A. Bobula , and Donn D'Alessio Echinacea for the Common Cold: Can Alternative Medicine Be Evidence-Based Medicine? Ronald B. Turner Echinacea for the Common Cold Steve Shober Echinacea for the Common Cold Paul Mittman , Debra Wollner , and Linda Kim Echinacea for the Common Cold Paul J. Millea Echinacea for the Common Cold Bruce Barrett Echinacea for the Common Cold Ethan B. Russo Echinacea for the Common Cold Seth G. Abrahams Metrics Cited ByAn Evidence-Based Systematic Review of Echinacea ( E. angustifolia DC, E. pallida, E. purpurea ) by the Natural Standard Research Collaboration 7 October 2003Volume 139, Issue 7Page: 599-600KeywordsClinical trialsCommon coldLymphoid tissueMetabolitesSurgery ePublished: 7 October 2003 Issue Published: 7 October 2003 CopyrightCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Abstract 1012: Patient-derived tumor microenvironment models uncover nonautonomous TKI resistance mechanisms in NSCLC
Authors: Haichuan Hu, Hillary Mulvey, Sundus Noeen, Kodack David, Aaron Hata, Matthew Niederst, Cyril Benes, Jeffrey Engelman
Journal: Cancer Research (2017)

Abstract Background: Tyrosine kinase inhibitors (TKI) have yielded great responses in non-small-cell lung cancer (NSCLC) with EGFR mutations and ALK translocations, however these and other targeted therapies are limited by intrinsic and acquired drug resistance. Previous study from our group was looking into tumor autonomous resistance mechanisms by developing patient-derived cancer models (PDCs). In this study, we aimed to decipher the non-autonomous resistance mechanisms via tumor microenvironment by developing patient-derived fibroblast (PDF) cell lines. Method: Cancer-associated fibroblast cells are isolated directly from EGFR mutant and ALK translocated NSCLC biopsies. Over 30 PDFs models have been established, which represent different clinical features and response profiles. Result: By co-culturing the PDCs with PDFs, we found that there is considerable variability in both models for their magnitude and mechanism by which the TKI treatment is desensitized. Both HGF dependent and HGF independent resistance mechanisms can be overcome by specific therapeutic combinations. Conclusion: Together, our results indicate that PDFs are clinically relevant models for deciphering non-autonomous resistance mechanisms, that they are heterogeneous in protecting cancer cells from TKI treatment, and that the resistance mediated by PDFs can be overcome by specific therapeutic combinations. Citation Format: Haichuan Hu, Hillary Mulvey, Sundus Noeen, Kodack David, Aaron Hata, Matthew Niederst, Cyril Benes, Jeffrey Engelman. Patient-derived tumor microenvironment models uncover nonautonomous TKI resistance mechanisms in NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1012. doi:10.1158/1538-7445.AM2017-1012
Personal View
Authors: P A Sykes
Journal: BMJ (1985)

<h3>ABSTRACT</h3> <h3>Background</h3> The coronavirus, which originated in Wuhan, causing the disease called COVID-19, spread more than 200 countries and continents end of the March. There is a lot of data since the virus started. However, these data will be explanatory when accurate analyzes are made and will allow future predictions to be made. In this study, it was aimed to model the outbreak with different time series models and also predict the indicators. <h3>Methods</h3> The data was collected from 25 countries which have different process at least 20 days. ARIMA(p,d,q), Simple Exponential Smoothing, Holt’s Two Parameter, Brown’s Double Exponential Smoothing Models were used. The prediction and forecasting values were obtained for the countries. Trends and seasonal effects were also evaluated. <h3>Results</h3> China has almost under control according to forecasting. The cumulative death prevalence in Italy and Spain will be the highest, followed by the Netherlands, France, England, China, Denmark, Belgium, Brazil and Sweden respectively as of the first week of April. The highest daily case prevalence was observed in Belgium, America, Canada, Poland, Ireland, Netherlands, France and Israel between 10% and 12%.The lowest rate was observed in China and South Korea. Turkey was one of the leading countries in terms of ranking these criteria. The prevalence of the new case and the recovered were higher in Spain than Italy. <h3>Conclusions</h3> More accurate predictions for the future can be obtained using time series models with a wide range of data from different countries by modelling real time and retrospective data.
IMMUNITY.CHAPTER XXII.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use.
Authors: Robert C. G. Martin, Anthony B. El-Khoueiry, Alec Goldenberg, Alan Paul Venook, Parvez Mantry, Pierre Michel Gholam, Brendan McGuire, Arun Sanyal, Jeff H. Geschwind, Jorge A. Marrero
Journal: Journal of Clinical Oncology (2012)

278 Background: GIDEON is a global, prospective, noninterventional study of patients (pts) treated with sorafenib (SOR) for unresectable hepatocellular carcinoma (uHCC). Regions evaluated included US, Europe, Japan, Asia Pacific, and Latin America. Detailed regional data were presented by Kudo et al (ILCA 2011, abstr 0-030). Data from the second US interim analysis are compared to global results. Methods: Eligible pts had uHCC and were treated with SOR. Demographics, disease etiology, treatment history, and SOR dosing were compared in a descriptive, preplanned subgroup analysis. Results: Global and US safety populations comprised 1571 and 313 pts, respectively. In the US, hepatitis B was less common (18% vs 37% global) whereas hepatitis C was more frequent (53% vs 32% global). Alcoholic liver disease etiology was higher in US pts (41% vs 29% global). US pts were diagnosed with later-stage disease, but fewer US pts had documented BCLC and Child-Pugh status. Fewer US pts had an ECOG PS 0 at start of SOR (28% vs 40% global). Rates of prior surgery and locoregional treatment were similar in US (11% and 49%, respectively) and global pts (19% and 55%, respectively). US pts treated with TACE (n = 116) underwent fewer TACE procedures (≥3: 13.8% vs 38.9% global); most (59%) TACE-treated pts in the US received 1 treatment. In US vs global pts, median time from prior surgery to start of SOR was 10 months (range 1-61) vs 14 months (range 1-181) and median time from last TACE to start of SOR was 3.2 months vs 3.1 months. Conclusions: Disease characteristics and treatment patterns for pts with uHCC in the US differ from those in the global population. US pts enrolled in GIDEON (ie, receiving SOR) have differing etiologies of liver disease and have a greater proportion of hepatic dysfunction, likely accounting for worse performance status. [Table: see text]
Cardiac Resynchronization for Progressive Heart Failure—Reply
Authors: David J. Bradley, Steven N. Goodman, Neil R. Powe
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chirurgie plastique des seins
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Paying Research Subjects: A Survey of Current Policies
Journal: Annals of Internal Medicine (2002)

Summaries for Patients5 March 2002Paying Research Subjects: A Survey of Current PoliciesSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-5-200203050-00004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Research organizations, such as universities and drug companies, sometimes pay people who participate in health-related research studies. People disagree about whether it is right to pay research subjects. Some worry that large payments might entice people to participate in research that without payment they would consider too risky. There are no clear rules about when to pay research subjects or how much it is appropriate to pay, so each research organization must create its own rules. Research organizations might benefit from knowing how others decide about paying research ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Paying Research Subjects: An Analysis of Current Policies.” It is in the 5 March 2002 issue of Annals of Internal Medicine (volume 136, pages 368-373). The authors are N Dickert, E Emanuel, and C Grady.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians–American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPaying Research Subjects: An Analysis of Current Policies Neal Dickert , Ezekiel Emanuel , and Christine Grady Metrics 5 March 2002Volume 136, Issue 5Page: I-38KeywordsDrugsInstitutional review boardsResearch and reporting methodsResearch designResearch ethicsResearch reporting guidelinesSurvey research ePublished: 5 March 2002 Issue Published: 5 March 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Spread of influenza.
Journal: BMJ (1967)

NVITIUI 67 defensive nature, it follows that antibiotics themselves have a function in suppressing other species than those forming them and thus securing a more liberal supply of nutrient." Nature red in tooth and claw," an expression intended to refer only to the animal kingdom, has thus an equivalent even among the lowest plants-a forbidding thought to the believer in peaceful co-existence as a natural way of life.